CompletedNot Applicable

Screening of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers

France55 participantsStarted 2012-03

Plain-language summary

In this prospective study, the investigators will implement a systematic screening program and 3-year follow-up in a cohort of asymptomatic BMPR2 mutation carriers. This study is designed to: * determine predictive factors (biological, functional, radiological and hemodynamic) of development of PAH * monitor these subjects' clinical, functional, biological, echocardiographic and hemodynamic characteristics * assess the risk of occurrence of PAH * screen patients with PAH at an early stage of disease and offer them an early management * constitute a collection of biological samples (0, 12, 24 months follow-up) of asymptomatic BMPR2 mutation carriers.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * men and women over 18 years old, * carriers of a BMPR2 mutation without known PAH, * having given his informed consent Exclusion Criteria: * men and women under 18 years old, * patients with a known PAH, * pregnant women, * adults protected, * detainees, * people in emergencies, * people refusing or unable to give informed consent, * no affiliation to a regime of social security.

What they're measuring

predictive factors of the occurrence of PAH

Timeframe: 2 years

Trial details

NCT IDNCT01600898

SponsorAssistance Publique - Hôpitaux de Paris

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2016-07

View on ClinicalTrials.gov More Pulmonary Arterial Hypertension trials